New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Demonstrate significant bleed reduction in hemophilia A and B
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
CMOs showed an increasing reluctance to take on debt in 2022
Subscribe To Our Newsletter & Stay Updated
